Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients

Key clinical point: Hypertensive patients hospitalized for COVID-19 had better 28-day survival if they were on ACE inhibitor or angiotensin receptor blocker treatment on admission.

Major finding: Propensity-matched analysis showed treatment with an ACE inhibitor/angiotensin receptor blocker was linked with a 63% reduced rate of 28-day all-cause mortality.

Study details: Retrospective analyses run on observational data from 3,430 hospitalized COVID-19 patients at nine Chinese hospitals admitted during Dec. 31, 2019–Feb. 20, 2020.

Disclosures: Dr. Zhang and coauthors had no commercial disclosures.


Zhang P et al. Circ Res. 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134.